Filing Flows

Filing Flows › Companies › Intellia Therapeutics › Cash flow

Intellia Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$86.3M in Q3 2026 · −$358M over twelve months

Operating cash flow−$85.4M
Capital spending−$888K
Free cash flow−$86.3M

Analysis

In Q3 2026, Intellia Therapeutics generated −$85.4M of operating cash flow and spent $888K on capital projects, leaving free cash flow of −$86.3M. That is $9.4M less than in Q3 2025 (−$76.9M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$355M; the largest uses were operating cash flow ($355M), capital spending ($2.9M); besides operations, cash came from other financing ($304M), other investing ($17.1M); the cash balance fell by $35.8M.

Operating cash flow was −$85.4M against net income of −$127M. The largest differences: stock-based pay +$14.4M, gains on investments +$10.4M, prepaid and other assets +$3.2M.

Free cash flow

Intellia Therapeutics: free cash flow by quarterIntellia Therapeutics: free cash flow by quarter−$86.2MQ4 2024−$150MQ1 2025−$99.9MQ2 2025−$76.9MQ3 2025−$69.4MQ4 2025−$117MQ1 2026−$84.9MQ2 2026−$86.3MQ3 2026
Operating cash flow less capital spending.
Intellia Therapeutics: operating cash flow against capital spendingIntellia Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$85.2M$981KQ4 2024−$149M$735KQ1 2025−$99.6M$239KQ2 2025−$76.9M$29KQ3 2025−$69.3M$126KQ4 2025−$117M$79KQ1 2026−$83.1M$1.8MQ2 2026−$85.4M$888KQ3 2026
Latest (Q3 2026): Operating cash flow −$85.4M, Capital spending $888K.

Capital allocation, year by year

Intellia Therapeutics: where the cash came from (up) and went (down), by fiscal yearIntellia Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$225MFY2021: Shares issued $1.9BFY2021: Capital spending −$12.8M$1.9BFY2021FY2022: Operating cash flow −$333MFY2022: Shares issued $14.5MFY2022: Asset sales $150KFY2022: Capital spending −$13.6MFY2022: Acquisitions −$287K$14.7MFY2022FY2023: Operating cash flow −$394MFY2023: Shares issued $126MFY2023: Capital spending −$14.0MFY2023: Acquisitions −$287K$126MFY2023FY2024: Operating cash flow −$349MFY2024: Shares issued $183MFY2024: Capital spending −$5.8MFY2024: Acquisitions −$287K$183MFY2024FY2025: Operating cash flow −$395MFY2025: Shares issued $129MFY2025: Capital spending −$1.1M$129MFY2025
Over these 5 years operating cash flow totalled −$1.7B; the largest uses were operating cash flow ($1.7B) and capital spending ($47.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$474M
Debt$73.7M
Net cash$400M
Cash runway16 months

Intellia Therapeutics is burning cash: its operations consume cash, a free cash flow of −$358M a year at the current rate against $474M of cash and investments: a runway of about 16 months before any new financing.

Where the cash came from and went

Intellia Therapeutics: sources (+) and uses (−) of cash, Q3 2026Intellia Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$85.4MOther financing$73.5MOther investing$62.6MCash drawn (+) / kept (−)−$50.0MCapital spending−$888KAsset & business sales$267K
Intellia Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Intellia Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$355MOther financing$304MCash drawn (+) / kept (−)$35.8MOther investing$17.1MCapital spending−$2.9MShares issued$641K

From profit to cash

Intellia Therapeutics: net income to operating cash flow, Q3 2026Intellia Therapeutics: net income to operating cash flow, Q3 2026Net income−$127MDepreciation & amortization$1.9MStock-based pay$14.4MGains on investments$10.4MGains on disposals−$221KReceivables−$178KPayables−$661KAccrued liabilities$2.5MPrepaid and other assets$3.2MOperating cash flow−$85.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$85.4M−$888K—−$50.0M−$86.3M
Q2 2026−$83.1M−$1.8M—$28.6M−$84.9M
Q1 2026−$117M−$79K—$17.5M−$117M
Q4 2025−$69.3M−$126K$625K$39.8M−$69.4M
Q3 2025−$76.9M−$29K$97K−$37.2M−$76.9M
Q2 2025−$99.6M−$239K—−$21.9M−$99.9M
Q1 2025−$149M−$735K—$54.6M−$150M
Q4 2024−$85.2M−$981K$1.0M−$68.7M−$86.2M

Intellia Therapeutics: income statement and cash flow

Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year). The chart follows the revenue to costs, profit and cash.

Intellia Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.